MTOR and non-small cell lung carcinoma: Additionally, 20 μM EGCG had improved gefitinib resistance by inducing cell death by affecting the phosphorylation of EPK as well as the inhibition of epithelial-Mesenchymal transition (EMT) and inhibition of the phosphatidylinositol-3-kinase (PI3K)/mTOR pathway in non-small cell lung cancer (NSCLC) cell lines [128].